BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Milic S, Štimac D. Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment. Dig Dis 2012;30:158-62. [DOI: 10.1159/000336669] [Cited by in Crossref: 124] [Cited by in F6Publishing: 122] [Article Influence: 12.4] [Reference Citation Analysis]
Number Citing Articles
1 Sorrenti V, Di Giacomo C, Acquaviva R, Cosenza J, Carota G, Galvano F. Blond and blood juice supplementation in high fat diet fed mice: effect on antioxidant status and DDAH/ADMA pathway. RSC Adv 2019;9:11406-12. [DOI: 10.1039/c9ra00669a] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Inafuku M, Matsuzaki G, Oku H. Intravenous Mycobacterium Bovis Bacillus Calmette-Guérin Ameliorates Nonalcoholic Fatty Liver Disease in Obese, Diabetic ob/ob Mice. PLoS One 2015;10:e0128676. [PMID: 26039731 DOI: 10.1371/journal.pone.0128676] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
3 Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Müllhaupt B, Geier A. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0142661. [PMID: 26565986 DOI: 10.1371/journal.pone.0142661] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
4 Seth RK, Kimono D, Alhasson F, Sarkar S, Albadrani M, Lasley SK, Horner R, Janulewicz P, Nagarkatti M, Nagarkatti P, Sullivan K, Chatterjee S. Increased butyrate priming in the gut stalls microbiome associated-gastrointestinal inflammation and hepatic metabolic reprogramming in a mouse model of Gulf War Illness. Toxicol Appl Pharmacol 2018;350:64-77. [PMID: 29751049 DOI: 10.1016/j.taap.2018.05.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
5 Griffin JD, Bejarano E, Wang XD, Greenberg AS. Integrated Action of Autophagy and Adipose Tissue Triglyceride Lipase Ameliorates Diet-Induced Hepatic Steatosis in Liver-Specific PLIN2 Knockout Mice. Cells 2021;10:1016. [PMID: 33923083 DOI: 10.3390/cells10051016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bozaykut P, Sahin A, Karademir B, Ozer NK. Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic steatohepatitis. Mechanisms of Ageing and Development 2016;157:17-29. [DOI: 10.1016/j.mad.2016.07.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
7 Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, Furlanello C, Zandonà A, Paci P, Capuani G, Dallapiccola B, Miccheli A, Alisi A, Putignani L. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta‐omics‐based approach. Hepatology 2016;65:451-64. [DOI: 10.1002/hep.28572] [Cited by in Crossref: 282] [Cited by in F6Publishing: 278] [Article Influence: 47.0] [Reference Citation Analysis]
8 Ma L, Yuan Y, Zhao M, Zhou X, Jehangir T, Wang F, Xi Y, Bu S. Mori Cortex extract ameliorates nonalcoholic fatty liver disease (NAFLD) and insulin resistance in high-fat-diet/streptozotocin-induced type 2 diabetes in rats. Chinese Journal of Natural Medicines 2018;16:411-7. [DOI: 10.1016/s1875-5364(18)30074-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Willebrords J, Pereira IV, Maes M, Crespo Yanguas S, Colle I, Van Den Bossche B, Da Silva TC, de Oliveira CP, Andraus W, Alves VA. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res. 2015;59:106-125. [PMID: 26073454 DOI: 10.1016/j.plipres.2015.05.002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 12.1] [Reference Citation Analysis]
10 Geng Y, Wang Y, Sun R, Kang X, Zhao H, Zhu M, Sun Y, Hu Y, Wang Z, Tian X, Zhao Y, Yao J. Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3. Toxicol Appl Pharmacol 2021;432:115758. [PMID: 34678374 DOI: 10.1016/j.taap.2021.115758] [Reference Citation Analysis]
11 Sakr HF, Abbas AM, Haidara MA. Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease. J Basic Clin Physiol Pharmacol 2018;29:61-71. [PMID: 29161233 DOI: 10.1515/jbcpp-2017-0069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
12 Lee J, Park J, Roh YS. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. Arch Pharm Res 2019;42:935-46. [DOI: 10.1007/s12272-019-01178-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
13 Zheng YP, Zhong XY, Huang YS, Zheng CB. HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats. Ann Hepatol 2018;17:511-8. [PMID: 29735802 DOI: 10.5604/01.3001.0011.7396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Biondo LA, Teixeira AAS, de O. S. Ferreira KC, Neto JCR. Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. CPD 2020;26:932-45. [DOI: 10.2174/1381612826666200122124116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
15 Sun S, Wu T, Wang M, Li W, Wang L, He S, Wei H, Song H, Ji G. The association between TCM syndromes and SCAP polymorphisms in subjects with non-alcoholic fatty liver disease. European Journal of Integrative Medicine 2013;5:386-92. [DOI: 10.1016/j.eujim.2013.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Abramovitz I, Zini A, Pribluda P, Kedem R, Zur D, Protter NE, Almoznino G. "Dental Cluster" Versus "Metabolic Cluster": Analyzing the Associations of Planned and Delivered Dental Procedures with Metabolic Syndrome, Utilizing Data from the Dental, Oral, Medical Epidemiological (DOME) Cross-Sectional Record-Based Nationwide Study. Biology (Basel) 2021;10:608. [PMID: 34209432 DOI: 10.3390/biology10070608] [Reference Citation Analysis]
17 Shang XR, Song JY, Liu FH, Ma J, Wang HJ. GWAS-Identified Common Variants With Nonalcoholic Fatty Liver Disease in Chinese Children. J Pediatr Gastroenterol Nutr 2015;60:669-74. [PMID: 25522307 DOI: 10.1097/MPG.0000000000000662] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
18 Koo HJ, Lee S, Chang KJ, Sohn E, Sohn EH, Kang SC, Pyo S. Hepatic anti-inflammatory effect of hexane extracts of Dioscorea batatas Decne: Possible suppression of toll-like receptor 4-mediated signaling. Biomed Pharmacother 2017;92:157-67. [PMID: 28538192 DOI: 10.1016/j.biopha.2017.05.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
20 Minuk GY, Iliant V, Zhou N, Kaita KD, Wong SG, Peretz D, Uhanova J. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. Liver Int 2018;38:1110-6. [DOI: 10.1111/liv.13644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Reid DT, Eksteen B. Murine models provide insight to the development of non-alcoholic fatty liver disease. Nutr Res Rev. 2015;28:133-142. [PMID: 26494024 DOI: 10.1017/s0954422415000128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
22 Feng WW, Kuang SY, Tu C, Ma ZJ, Pang JY, Wang YH, Zang QC, Liu TS, Zhao YL, Xiao XH, Wang JB. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomed Pharmacother 2018;99:325-33. [PMID: 29353208 DOI: 10.1016/j.biopha.2018.01.071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
23 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
24 Morita T, Yamazaki Y, Fujiharu C, Ishii T, Seto M, Nishinoue N, Sasaki Y, Kawato T, Motohashi M, Maeno M. Serum γ-glutamyltransferase level is associated with periodontal disease independent of drinking habits in Japanese adults. Med Sci Monit 2014;20:2109-16. [PMID: 25360830 DOI: 10.12659/MSM.891204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
25 Chen G, Xu R, Zhang S, Wang Y, Wang P, Edin ML, Zeldin DC, Wang DW. CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice. Am J Physiol Endocrinol Metab 2015;308:E97-E110. [PMID: 25389366 DOI: 10.1152/ajpendo.00366.2014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
26 Mahmoudi L, Asadi S, Al-Mousavi Z, Niknam R. A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease. Clin Nutr 2021;40:2999-3005. [PMID: 33341312 DOI: 10.1016/j.clnu.2020.11.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ganz M, Szabo G. Immune and inflammatory pathways in NASH. Hepatol Int. 2013;7 Suppl 2:771-781. [PMID: 24587847 DOI: 10.1007/s12072-013-9468-6] [Cited by in Crossref: 104] [Cited by in F6Publishing: 100] [Article Influence: 11.6] [Reference Citation Analysis]
28 Ooi GJ, Burton PR, Doyle L, Wentworth JM, Bhathal PS, Sikaris K, Cowley MA, Roberts SK, Kemp W, O’brien PE, Brown WA. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. OBES SURG 2017;27:115-25. [DOI: 10.1007/s11695-016-2246-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
29 Chheda TK, Shivakumar P, Sadasivan SK, Chanderasekharan H, Moolemath Y, Oommen AM, Madanahalli JR, Marikunte VV. Fast food diet with CCl4 micro-dose induced hepatic-fibrosis--a novel animal model. BMC Gastroenterol. 2014;14:89. [PMID: 24884574 DOI: 10.1186/1471-230x-14-89] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol. 2012;2:132. [PMID: 23112961 DOI: 10.3389/fcimb.2012.00132.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Sepehrimanesh M, Niknam R, Ejtehadi F, Fattahi MR, Safarpour A. Association Between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome with Gallstone Disease, South Iran: A Population-Based Study. Diabetes Metab Syndr Obes 2020;13:1449-58. [PMID: 32431528 DOI: 10.2147/DMSO.S246949] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Birerdinc A, Younossi Z. Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease? Journal of Hepatology 2015;62:761-2. [DOI: 10.1016/j.jhep.2015.01.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
33 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
34 Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol 2012;2:132. [PMID: 23112961 DOI: 10.3389/fcimb.2012.00132] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
35 Boga S, Koksal AR, Alkim H, Yilmaz Ozguven MB, Bayram M, Ergun M, Sisman G, Tekin Neijmann S, Alkim C. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH. Metab Syndr Relat Disord. 2015;13:393-399. [PMID: 26367098 DOI: 10.1089/met.2015.0046] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
36 Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:519-527. [PMID: 25617046 DOI: 10.1586/17474124.2015.1004312] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
37 Wu S, Tu R, Zheng E, Shi Y, Liu G. Findings and Implications of Focal Fatty Sparing of the Liver at Follow-up: A Preliminary Study Based on Sonography, Computed Tomography, and Magnetic Resonance Imaging. Journal of Ultrasound in Medicine 2013;32:1695-702. [DOI: 10.7863/ultra.32.10.1695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28:40-51. [PMID: 23286927 DOI: 10.1177/0884533612470464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
39 Yilmaz M, Odabas O, Karaaslan M, Guler OF, Toprak T, Bicer S, Tonyali S. Predicting risk of erectile dysfunction in patients with nonalcoholic fatty liver disease. Andrologia 2021;53:e14091. [PMID: 33951744 DOI: 10.1111/and.14091] [Reference Citation Analysis]
40 Kim TH, Jeong CW, Jun HY, Lee C, Noh S, Kim JE, Kim S, Yoon KH. Accuracy of proton magnetic resonance for diagnosing non-alcoholic steatohepatitis: a meta-analysis. Sci Rep 2019;9:15002. [PMID: 31628409 DOI: 10.1038/s41598-019-51302-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Ceccarelli S, Panera N, Gnani D, Nobili V. Dual Role of MicroRNAs in NAFLD. Int J Mol Sci. 2013;14:8437-8455. [PMID: 23594995 DOI: 10.3390/ijms14048437] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
42 Li TT, Tan TB, Hou HQ, Zhao XY. Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease. Lipids Health Dis 2018;17:256. [PMID: 30428868 DOI: 10.1186/s12944-018-0901-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
43 Khan SA, Wollaston-Hayden EE, Markowski TW, Higgins L, Mashek DG. Quantitative analysis of the murine lipid droplet-associated proteome during diet-induced hepatic steatosis. J Lipid Res 2015;56:2260-72. [PMID: 26416795 DOI: 10.1194/jlr.M056812] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
44 Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol 2014; 6(11): 800-811 [PMID: 25429318 DOI: 10.4254/wjh.v6.i11.800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
45 Andrade RSBD, França LFDC, Pessoa LDS, Landim BDAA, Rodrigues AA, Alves EHP, Lenardo DD, Nascimento HMS, Sousa FBDM, Barbosa ALDR, Medeiros JR, Vasconcelos ACCG, Vasconcelos DFP. High‐fat diet aggravates the liver disease caused by periodontitis in rats. J Periodontol 2019;90:1023-31. [DOI: 10.1002/jper.18-0564] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
46 Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 2014;5:21. [PMID: 25937854 DOI: 10.1186/1878-5085-5-21] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
47 Jeong HS, Kim KH, Lee IS, Park JY, Kim Y, Kim KS, Jang HJ. Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice. Biomed Pharmacother. 2017;88:625-634. [PMID: 28142119 DOI: 10.1016/j.biopha.2017.01.114] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
48 Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, Li Q, Li N. Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. PLoS One. 2015;10:e0142808. [PMID: 26566287 DOI: 10.1371/journal.pone.0142808] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
49 Xue L, He J, Gao N, Lu X, Li M, Wu X, Liu Z, Jin Y, Liu J, Xu J, Geng Y. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017;7:45176. [PMID: 28349964 DOI: 10.1038/srep45176] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 19.2] [Reference Citation Analysis]
50 Bazzocchi A, Diano D, Albisinni U, Marchesini G, Battista G, Guglielmi G. Liver in the analysis of body composition by dual-energy X-ray absorptiometry. Br J Radiol 2014;87:20140232. [PMID: 24919499 DOI: 10.1259/bjr.20140232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
51 Xiao J, Han N, Yang D, Zhao H. Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: characteristics and independent risk factors. Virol J 2013;10:261. [PMID: 23941464 DOI: 10.1186/1743-422X-10-261] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
52 Kahle M, Horsch M, Fridrich B, Seelig A, Schultheiß J, Leonhardt J, Irmler M, Beckers J, Rathkolb B, Wolf E, Franke N, Gailus-Durner V, Fuchs H, de Angelis MH, Neschen S. Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis. Mol Metab 2013;2:435-46. [PMID: 24327959 DOI: 10.1016/j.molmet.2013.07.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
53 Schütte K, Kipper M, Kahl S, Bornschein J, Götze T, Adolf D, Arend J, Seidensticker R, Lippert H, Ricke J. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion. 2013;87:147-159. [PMID: 23548687 DOI: 10.1159/000346743] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
54 Boga S, Munoz-Abraham AS, Rodriguez-Davalos MI, Emre SH, Jain D, Schilsky ML. Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis. World J Hepatol 2016; 8(15): 659-664 [PMID: 27239259 DOI: 10.4254/wjh.v8.i15.659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Khullar V, Dolganiuc A, Firpi RJ. Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant 2014; 4(2): 81-92 [PMID: 25032097 DOI: 10.5500/wjt.v4.i2.81] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
56 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
57 Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 2014; 20(45): 16831-16840 [PMID: 25492997 DOI: 10.3748/wjg.v20.i45.16831] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
58 Yuan C, Lu L, An B, Jin W, Dong Q, Xin Y, Xuan S. Association Between LYPLAL1 rs12137855 Polymorphism With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease in a Chinese Han Population. Hepat Mon 2015;15:e33155. [PMID: 26977168 DOI: 10.5812/hepatmon.33155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
59 Ou Q, Zhao Y, Zhou J, Wu X. Comprehensive circular RNA expression profiles in a mouse model of nonalcoholic steatohepatitis. Mol Med Rep 2019;19:2636-48. [PMID: 30720095 DOI: 10.3892/mmr.2019.9935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
60 Nourian M, Askari G, Golshiri P, Miraghajani M, Shokri S, Arab A. Effect of lifestyle modification education based on health belief model in overweight/obese patients with non-alcoholic fatty liver disease: A parallel randomized controlled clinical trial. Clin Nutr ESPEN 2020;38:236-41. [PMID: 32690164 DOI: 10.1016/j.clnesp.2020.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
61 Albracht-Schulte K, Rosairo S, Ramalingam L, Wijetunge S, Ratnayake R, Kotakadeniya H, Dawson JA, Kalupahana NS, Moustaid-Moussa N. Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women. Diabetes Metab Syndr Obes. 2019;12:863-872. [PMID: 31354322 DOI: 10.2147/dmso.s203937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
62 Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Dig Dis Sci 2015;60:3194-202. [PMID: 26017679 DOI: 10.1007/s10620-015-3728-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
63 Mikolasevic I, Orlic L, Milic S, Lukenda V, Racki S, Stimac D, Avdovic E, Zaputovic L. Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease. Wien Klin Wochenschr. 2014;126:474-479. [PMID: 24652022 DOI: 10.1007/s00508-014-0538-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
64 Mikolasevic I, Racki S, Lukenda V, Milic S, Pavletic-persic M, Orlic L. Nonalcoholic Fatty Liver Disease in Renal Transplant Recipients Proven by Transient Elastography. Transplantation Proceedings 2014;46:1347-52. [DOI: 10.1016/j.transproceed.2014.02.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
65 Miyagawa K, Oe S, Honma Y, Izumi H, Baba R, Harada M. Lipid-Induced Endoplasmic Reticulum Stress Impairs Selective Autophagy at the Step of Autophagosome-Lysosome Fusion in Hepatocytes. Am J Pathol 2016;186:1861-73. [PMID: 27157992 DOI: 10.1016/j.ajpath.2016.03.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
66 Lu J, Fang B, Ren M, Huang G, Zhang S, Wang Y, Deng X, Guan S. Nonalcoholic fatty liver disease induced by 13-week oral administration of 1,3-dichloro-2-propanol in C57BL/6J mice. Environmental Toxicology and Pharmacology 2015;39:1115-21. [DOI: 10.1016/j.etap.2015.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
67 Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B, Nobili V, Lorenza P. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci. 2014;15:684-711. [PMID: 24402126 DOI: 10.3390/ijms15010684] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
68 Liu J, Yuan Y, Gong X, Zhang L, Zhou Q, Wu S, Zhang X, Hu J, Kuang G, Yin X, Wan J, Yuan Y. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. Int Immunopharmacol 2020;80:106208. [PMID: 31955065 DOI: 10.1016/j.intimp.2020.106208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
69 Clanton J, Subichin M. The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis. Surg Clin North Am. 2016;96:703-715. [PMID: 27473796 DOI: 10.1016/j.suc.2016.03.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
70 Cakmak E, Duksal F, Altinkaya E, Acibucu F, Dogan OT, Yonem O, Yilmaz A. Association between the severity of nocturnal hypoxia in obstructive sleep apnea and non-alcoholic fatty liver damage. Hepat Mon. 2015;15:e32655. [PMID: 26834793 DOI: 10.5812/hepatmon.32655] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
71 Giannelli G, Mikulits W, Dooley S, Fabregat I, Moustakas A, ten Dijke P, Portincasa P, Winter P, Janssen R, Leporatti S, Herrera B, Sanchez A. The rationale for targeting TGF-β in chronic liver diseases. Eur J Clin Invest 2016;46:349-61. [PMID: 26823073 DOI: 10.1111/eci.12596] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
72 Roychowdhury S, Selvakumar PC, Cresci GAM. The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. Med Sci (Basel) 2018;6:E47. [PMID: 29874807 DOI: 10.3390/medsci6020047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
73 Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther 2015;9:4835-45. [PMID: 26316717 DOI: 10.2147/DDDT.S64877] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
74 Lin Y, Wang S, Gao L, Zhou Z, Yang Z, Lin J, Ren S, Xing H, Wu B. Oscillating lncRNA Platr4 regulates NLRP3 inflammasome to ameliorate nonalcoholic steatohepatitis in mice. Theranostics 2021;11:426-44. [PMID: 33391484 DOI: 10.7150/thno.50281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
75 Ni X, Jiao L, Zhang Y, Xu J, Zhang Y, Zhang X, Du Y, Sun Z, Wang S. Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. Int J Gen Med 2021;14:3439-44. [PMID: 34285567 DOI: 10.2147/IJGM.S317081] [Reference Citation Analysis]
76 Ables GP. Update on pparγ and nonalcoholic Fatty liver disease. PPAR Res 2012;2012:912351. [PMID: 22966224 DOI: 10.1155/2012/912351] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
77 Roh JS, Lee H, Lim J, Kim J, Yang H, Yoon Y, Shin SS, Yoon M. Effect of Gangjihwan on hepatic steatosis and inflammation in high fat diet-fed mice. Journal of Ethnopharmacology 2017;206:315-26. [DOI: 10.1016/j.jep.2017.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
78 Linden MA, Lopez KT, Fletcher JA, Morris EM, Meers GM, Siddique S, Laughlin MH, Sowers JR, Thyfault JP, Ibdah JA, Rector RS. Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats. Appl Physiol Nutr Metab 2015;40:1038-47. [PMID: 26394261 DOI: 10.1139/apnm-2015-0236] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
79 Zhang SS, Wang LY. Frontiers and prospects of pharmacotherapy for non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(2): 73-79 [DOI: 10.11569/wcjd.v27.i2.73] [Reference Citation Analysis]
80 Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:8713-8742. [PMID: 24837835 DOI: 10.3390/ijms15058713] [Cited by in Crossref: 148] [Cited by in F6Publishing: 141] [Article Influence: 18.5] [Reference Citation Analysis]
81 Hirsova P, Ibrahim SH, Bronk SF, Yagita H, Gores GJ. Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS One. 2013;8:e70599. [PMID: 23894677 DOI: 10.1371/journal.pone.0070599] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 7.2] [Reference Citation Analysis]
82 Fang J, Sun X, Xue B, Fang N, Zhou M. Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier. Evid Based Complement Alternat Med 2017;2017:2945803. [PMID: 29259643 DOI: 10.1155/2017/2945803] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
83 Li J, Wang T, Xia J, Yao W, Huang F. Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases. FASEB J 2019;33:11640-54. [PMID: 31370704 DOI: 10.1096/fj.201901175R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
84 Al Zarzour RH, Ahmad M, Asmawi MZ, Kaur G, Saeed MAA, Al-Mansoub MA, Saghir SAM, Usman NS, Al-Dulaimi DW, Yam MF. Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. Nutrients. 2017;9:776. [PMID: 28718838 DOI: 10.3390/nu9070766] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
85 Kim TH, Kim JE, Ryu JH, Jeong CW. Development of liver surface nodularity quantification program and its clinical application in nonalcoholic fatty liver disease. Sci Rep 2019;9:9994. [PMID: 31292497 DOI: 10.1038/s41598-019-46442-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
86 Mikolasevic I, Racki S, Zaputovic L, Lukenda V, Milic S, Orlic L. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients. Med Hypotheses 2014;82:205-8. [PMID: 24365277 DOI: 10.1016/j.mehy.2013.11.039] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
87 Grootjans J, Kaser A, Kaufman RJ, Blumberg RS. The unfolded protein response in immunity and inflammation. Nat Rev Immunol 2016;16:469-84. [PMID: 27346803 DOI: 10.1038/nri.2016.62] [Cited by in Crossref: 332] [Cited by in F6Publishing: 310] [Article Influence: 55.3] [Reference Citation Analysis]
88 Lum JHM, Cheah MCC, Leow WQ, Wan WK, Lim TKH, Chow WC, Chang JPE, Goh GBB. Clinical profile of non-alcoholic fatty liver disease in nonobese patients. J Gastroenterol Hepatol 2021;36:257-61. [PMID: 32557741 DOI: 10.1111/jgh.15154] [Reference Citation Analysis]
89 Chen H, Bai J, Dong F, Fang H, Zhang Y, Meng W, Liu B, Luo Y, Liu M, Bai Y, Abdul-Ghani MA, Li R, Wu J, Zeng R, Zhou Z, Dong LQ, Liu F. Hepatic DsbA-L protects mice from diet-induced hepatosteatosis and insulin resistance. FASEB J 2017;31:2314-26. [PMID: 28232481 DOI: 10.1096/fj.201600985R] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
90 Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, Boutari C, Doumas M, Karagiannis A, Mikhailidis DP. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-7868 [PMID: 26167086 DOI: 10.3748/wjg.v21.i25.7860] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 66] [Article Influence: 11.6] [Reference Citation Analysis]
91 Peyrou M, Bourgoin L, Poher AL, Altirriba J, Maeder C, Caillon A, Fournier M, Montet X, Rohner-Jeanrenaud F, Foti M. Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice. J Hepatol 2015;62:421-9. [PMID: 25234947 DOI: 10.1016/j.jhep.2014.09.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
92 Cansanção K, Silva Monteiro L, Carvalho Leite N, Dávalos A, Tavares do Carmo MDG, Arantes Ferreira Peres W. Advanced Liver Fibrosis Is Independently Associated with Palmitic Acid and Insulin Levels in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2018;10:E1586. [PMID: 30380656 DOI: 10.3390/nu10111586] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
93 Wu PJ, Chen JB, Lee WC, Ng HY, Lien SC, Tsai PY, Wu CH, Lee CT, Chiou TT. Oxidative Stress and Nonalcoholic Fatty Liver Disease in Hemodialysis Patients. Biomed Res Int 2018;2018:3961748. [PMID: 30515395 DOI: 10.1155/2018/3961748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
94 Farag HAM, Hosseinzadeh-Attar MJ, Muhammad BA, Esmaillzadeh A, Bilbeisi AHE. Comparative effects of vitamin D and vitamin C supplementations with and without endurance physical activity on metabolic syndrome patients: a randomized controlled trial. Diabetol Metab Syndr 2018;10:80. [PMID: 30455745 DOI: 10.1186/s13098-018-0384-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
95 Gupte AA, Lyon CJ, Hsueh WA. Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis. Curr Diab Rep. 2013;13:362-371. [PMID: 23475581 DOI: 10.1007/s11892-013-0372-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
96 Kurek K, Piotrowska DM, Wiesiołek-Kurek P, Łukaszuk B, Chabowski A, Górski J, Zendzian-Piotrowska M. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int 2014;34:1074-83. [PMID: 24106929 DOI: 10.1111/liv.12331] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 9.0] [Reference Citation Analysis]
97 Tyrovolas S, Panagiotakos DB, Georgousopoulou EN, Chrysohoou C, Skoumas J, Pan W, Tousoulis D, Pitsavos C. The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study. Therap Adv Gastroenterol 2019;12:1756284819858039. [PMID: 31258620 DOI: 10.1177/1756284819858039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
98 Mishra AK, Dubey V, Ghosh AR. Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota. Metabolism. 2016;65:48-65. [PMID: 26683796 DOI: 10.1016/j.metabol.2015.10.008] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 10.6] [Reference Citation Analysis]
99 Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 2014; 20(28): 9330-9337 [PMID: 25071327 DOI: 10.3748/wjg.v20.i28.9330] [Cited by in F6Publishing: 123] [Reference Citation Analysis]
100 Cantero I, Elorz M, Abete I, Marin BA, Herrero JI, Monreal JI, Benito A, Quiroga J, Martínez A, Huarte MP, Uriz-Otano JI, Tur JA, Kearney J, Martinez JA, Zulet MA. Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults. Int J Med Sci 2019;16:75-83. [PMID: 30662331 DOI: 10.7150/ijms.28044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
101 Mao Y, Yu F, Wang J, Guo C, Fan X. Autophagy: a new target for nonalcoholic fatty liver disease therapy. Hepat Med. 2016;8:27-37. [PMID: 27099536 DOI: 10.2147/hmer.s98120] [Cited by in Crossref: 60] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
102 Abenavoli L, Peta V, Milic N. Lifestyle changes associated with a new antioxidant formulation in non-alcoholic fatty liver disease: a case series. Annals of Hepatology 2015;14:121-6. [DOI: 10.1016/s1665-2681(19)30809-9] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract 2014;2014:847539. [PMID: 24729784 DOI: 10.1155/2014/847539] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
104 Ghamarchehreh ME, Jonaidi-Jafari N, Bigdeli M, Khedmat H, Saburi A. Iron Status and Metabolic Syndrome in Patients with Non-Alcoholic Fatty Liver Disease. Middle East J Dig Dis. 2016;8:31-38. [PMID: 26933479 DOI: 10.15171/mejdd.2016.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
105 Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30. [PMID: 24843641 DOI: 10.1111/jdi.12065] [Cited by in Crossref: 155] [Cited by in F6Publishing: 132] [Article Influence: 19.4] [Reference Citation Analysis]
106 Zhang Y, Yu L, Cai W, Fan S, Feng L, Ji G, Huang C. Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice. Sci Rep 2014;4:7375. [PMID: 25487878 DOI: 10.1038/srep07375] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
107 Cetin EG, Demir N, Sen I. The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. Sisli Etfal Hastan Tip Bul 2020;54:411-5. [PMID: 33364879 DOI: 10.14744/SEMB.2018.83604] [Reference Citation Analysis]
108 Wu S, Tu R, Liu G. Frequency and implication of focal fatty sparing in segmental homogeneous fatty liver at ultrasound. J Med Ultrasonics 2013;40:393-8. [DOI: 10.1007/s10396-013-0440-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Milic S, Mikolasevic I, Orlic L, Devcic E, Starcevic-Cizmarevic N, Stimac D, Kapovic M, Ristic S. The Role of Iron and Iron Overload in Chronic Liver Disease. Med Sci Monit. 2016;22:2144-2151. [PMID: 27332079 DOI: 10.12659/msm.896494] [Cited by in Crossref: 60] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
110 Liu R, Liu Q, He Y, Shi W, Xu Q, Yuan Q, Lin Q, Li B, Ye L, Min Y, Zhu P, Shao Y. Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. Medicine (Baltimore). 2019;98:e17781. [PMID: 31689846 DOI: 10.1097/md.0000000000017781] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
111 Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, Ashktorab H. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61:1214-1225. [PMID: 27038448 DOI: 10.1007/s10620-016-4143-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 13.8] [Reference Citation Analysis]
112 Panera N, Gnani D, Crudele A, Ceccarelli S, Nobili V, Alisi A. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(41): 15079-15086 [PMID: 25386056 DOI: 10.3748/wjg.v20.i41.15079] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
113 Martinelli I, Micioni Di Bonaventura MV, Moruzzi M, Amantini C, Maggi F, Gabrielli MG, Fruganti A, Marchegiani A, Dini F, Marini C, Polidori C, Lupidi G, Amenta F, Tayebati SK, Cifani C, Tomassoni D. Effects of Prunus cerasus L. Seeds and Juice on Liver Steatosis in an Animal Model of Diet-Induced Obesity. Nutrients 2020;12:E1308. [PMID: 32375317 DOI: 10.3390/nu12051308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
114 Wang G, Corwin MT, Olson KA, Badawi RD, Sarkar S. Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol. 2018;63:155004. [PMID: 29847315 DOI: 10.1088/1361-6560/aac8cb] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
115 Dibaise JK, Foxx-Orenstein AE. Role of the gastroenterologist in managing obesity. Expert Rev Gastroenterol Hepatol 2013;7:439-51. [PMID: 23899283 DOI: 10.1586/17474124.2013.811061] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
116 Guo B, Li Z. Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases. Front Genet 2014;5:242. [PMID: 25120559 DOI: 10.3389/fgene.2014.00242] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
117 Szanto KB, Li J, Cordero P, Oben JA. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367. [PMID: 30936733 DOI: 10.2147/dmso.s182331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
118 Ariya M, Koohpayeh F, Ghaemi A, Osati S, Davoodi SH, Razzaz JM, Javedan G, Ehrampoush E, Homayounfar R. Assessment of the association between body composition and risk of non-alcoholic fatty liver. PLoS One 2021;16:e0249223. [PMID: 33793621 DOI: 10.1371/journal.pone.0249223] [Reference Citation Analysis]
119 Krolow GK, Garcia E, Schoor F, Araujo FBS, Coral GP. Obstructive sleep apnea and severity of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2021;33:1104-9. [PMID: 32925501 DOI: 10.1097/MEG.0000000000001920] [Reference Citation Analysis]
120 Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73:1969-1987. [PMID: 26894897 DOI: 10.1007/s00018-016-2161-x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 15.2] [Reference Citation Analysis]
121 Han P, Sun D, Yang J. Interaction between periodontitis and liver diseases. Biomed Rep 2016;5:267-76. [PMID: 27588170 DOI: 10.3892/br.2016.718] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
122 Wu MJ, Yuan C, Lu LL, An BQ, Xuan SY, Xin YN. Role of NCAN rs2228603 polymorphism in the incidence of nonalcoholic fatty liver disease: a case-control study. Lipids Health Dis 2016;15:207. [PMID: 27887608 DOI: 10.1186/s12944-016-0367-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 Boga S, Alkim H, Koksal AR, Bayram M, Ozguven MBY, Ergun M, Neijmann ST, Ozgon G, Alkim C. Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology. Journal of Investigative Medicine 2015;63:871-7. [DOI: 10.1097/jim.0000000000000230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
124 Wang Q, Ye F, Ma P, Chen F, Che Y, Zhao X, Yang L. Quantitative magnetic resonance imaging evaluation of hepatic fat content with iron deposition: will it be disturbed? J Int Med Res 2019;47:1958-74. [PMID: 30859893 DOI: 10.1177/0300060519836033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]